$AKBA
Akebia Therapeutics, Inc. Stock $akba

$akba Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000162828021015865 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$52.91M	$90.14M
YoY Change	-41.3%	-10.58%
Cost Of Revenue	$52.50M	$174.6M
YoY Change	-69.94%	363.55%
Gross Profit	$418.0K	-$84.47M
YoY Change	-100.49%	-233.8%
Gross Profit Margin	0.79%	-93.71%
Selling, General & Admin	$41.65M	$35.48M
YoY Change	17.39%	-1.62%
% of Gross Profit	9964.35%
Research & Development	$37.21M	$52.82M
YoY Change	-29.54%	-38.36%
% of Gross Profit	8902.87%
Depreciation & Amortization	$9.513M	$500.0K
YoY Change	1802.6%	-16.67%
% of Gross Profit	2275.84%
Operating Expenses	$79.76M	$89.35M
YoY Change	-10.73%	-27.16%
Operating Profit	-$79.34M	-$173.8M
YoY Change	-54.35%	192.02%
Interest Expense	-$4.962M	-$2.308M
YoY Change	114.99%	-575.88%
% of Operating Profit
Other Income/Expense, Net	$1.265M	-$1.932M
YoY Change	-165.48%	-480.31%
Pretax Income	-$83.04M	-$175.8M
YoY Change	-52.75%	197.81%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$83.04M	-$175.8M
YoY Change	-52.75%	202.13%
Net Earnings / Revenue	-156.93%	-194.97%
Basic Earnings Per Share	-$0.51	-$1.28
Diluted Earnings Per Share	-$0.51	-$1.28
COMMON SHARES
Basic Shares Outstanding	161.3M shares
Diluted Shares Outstanding	161.3M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$247.0M	$295.3M
YoY Change	-16.36%	115.92%
Cash & Equivalents	$247.0M	$245.4M
Short-Term Investments	$0.00	$49.90M
Other Short-Term Assets	$11.18M	$10.00M
YoY Change	11.81%	-65.03%
Inventory	$37.90M	$104.6M
Prepaid Expenses
Receivables	$35.01M	$39.12M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$331.1M	$449.1M
YoY Change	-26.28%	41.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.670M	$9.380M
YoY Change	-18.23%	-13.97%
Goodwill	$55.10M	$55.10M
YoY Change	0.0%	0.09%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$67.47M	$47.27M
YoY Change	42.74%	-52.98%
Total Long-Term Assets	$280.8M	$296.1M
YoY Change	-5.16%	-41.62%
TOTAL ASSETS
Total Short-Term Assets	$331.1M	$449.1M
Total Long-Term Assets	$280.8M	$296.1M
Total Assets	$611.9M	$745.2M
YoY Change	-17.89%	-9.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$41.98M	$29.41M
YoY Change	42.74%	52.23%
Accrued Expenses	$111.7M	$142.8M
YoY Change	-21.77%	13.38%
Deferred Revenue	$11.87M	$23.53M
YoY Change	-49.56%	-41.64%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$165.6M	$195.8M
YoY Change	-15.42%	5.47%
LONG-TERM LIABILITIES
Long-Term Debt	$96.92M	$76.34M
YoY Change	26.96%
Other Long-Term Liabilities	$85.36M	$41.51M
YoY Change	105.65%	38.83%
Total Long-Term Liabilities	$182.3M	$117.8M
YoY Change	54.68%	294.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$165.6M	$195.8M
Total Long-Term Liabilities	$182.3M	$117.8M
Total Liabilities	$437.2M	$374.9M
YoY Change	16.62%	23.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.330B	-$1.031B
YoY Change	29.07%	59.78%
Common Stock	$1.505B	$1.401B
YoY Change	7.42%	20.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$174.6M	$370.3M
YoY Change
Total Liabilities & Shareholders Equity	$611.9M	$745.2M
YoY Change	-17.89%	-9.51%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$83.04M	-$175.8M
YoY Change	-52.75%	202.13%
Depreciation, Depletion And Amortization	$9.513M	$500.0K
YoY Change	1802.6%	-16.67%
Cash From Operating Activities	-$63.14M	$37.22M
YoY Change	-269.63%	-197.0%
INVESTING ACTIVITIES
Capital Expenditures	$1.000K	-$50.00K
YoY Change	-102.0%	-97.47%
Acquisitions
YoY Change
Other Investing Activities	$20.00M	-$49.96M
YoY Change	-140.03%	-189.2%
Cash From Investing Activities	$20.00M	-$50.00M
YoY Change	-140.0%	-192.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	37.37M	142.8M
YoY Change	-73.84%	1521.0%
NET CHANGE
Cash From Operating Activities	-63.14M	37.22M
Cash From Investing Activities	20.00M	-50.00M
Cash From Financing Activities	37.37M	142.8M
Net Change In Cash	-5.770M	130.0M
YoY Change	-104.44%	431.17%
FREE CASH FLOW
Cash From Operating Activities	-$63.14M	$37.22M
Capital Expenditures	$1.000K	-$50.00K
Free Cash Flow	-$63.14M	$37.27M
YoY Change	-269.41%	-202.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001517022
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36352
	dei	Entity Registrant Name EntityRegistrantName	AKEBIA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8756903
	dei	Entity Address Address Line1 EntityAddressAddressLine1	245 First Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	871-2098
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	AKBA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	174537458	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	246992000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228698000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39992000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	37898000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	61017000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35005000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26853000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11181000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14877000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	331076000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	371437000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7670000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8622000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24442000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26876000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	55053000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	55053000	USD
CY2021Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	126148000	USD
CY2020Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	144170000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67474000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111742000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	130624000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37981000	USD
CY2021Q2	us-gaap	Assets Assets	611863000	USD
CY2020Q4	us-gaap	Assets Assets	644139000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	41984000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	41308000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11869000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15214000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	165595000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	187146000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16598000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25345000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21735000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24621000	USD
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1930000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	2420000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96917000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96378000	USD
CY2021Q2	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	49094000	USD
CY2020Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	0	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	85363000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	60611000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	437232000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	396521000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169651423	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169651423	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148074085	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148074085	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	69079000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1504752000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1425115000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1330129000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1177511000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	174631000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	247618000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	611863000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	644139000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52913000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90142000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	105217000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	178620000	USD
CY2021Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	43484000	USD
CY2020Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	49988000	USD
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	68601000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9101000	USD
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	18021000	USD
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	18201000	USD
CY2021Q2	akba	Production Related Impairments Or Charges Intangibles ProductionRelatedImpairmentsOrChargesIntangibles	0	USD
CY2020Q2	akba	Production Related Impairments Or Charges Intangibles ProductionRelatedImpairmentsOrChargesIntangibles	115527000	USD
	akba	Production Related Impairments Or Charges Intangibles ProductionRelatedImpairmentsOrChargesIntangibles	0	USD
	akba	Production Related Impairments Or Charges Intangibles ProductionRelatedImpairmentsOrChargesIntangibles	115527000	USD
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	52495000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	174616000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	87100000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	202329000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37214000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52819000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77825000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134050000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41651000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73465000	USD
CY2021Q2	akba	License Expense LicenseExpense	894000	USD
CY2020Q2	akba	License Expense LicenseExpense	1044000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35482000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	82979000	USD
	akba	License Expense LicenseExpense	1590000	USD
	akba	License Expense LicenseExpense	1720000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	79759000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	89345000	USD
	us-gaap	Operating Expenses OperatingExpenses	162394000	USD
	us-gaap	Operating Expenses OperatingExpenses	209235000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-79341000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-173819000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-144277000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-232944000	USD
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4962000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2308000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9768000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4280000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1265000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	376000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1427000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	726000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-83038000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-175751000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-152618000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-236498000	USD
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.78
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	161329990	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	136906968	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	157596143	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	132651066	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-83038000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-175751000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-152618000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-236498000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83041000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175760000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-152625000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-236507000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394757000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56575000	USD
CY2020Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	451000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4916000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	412000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-60747000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	396364000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	142383000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6864000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	409000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-175751000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	370260000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	247618000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29498000	USD
CY2021Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5992000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	213891000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37266000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6515000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-83038000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	174631000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-152618000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-236498000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1012000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1045000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18021000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18201000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	115527000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	15000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	USD
	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	4427000	USD
	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	0	USD
	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	116000	USD
	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	0	USD
	akba	Noncash Interest Expense NoncashInterestExpense	539000	USD
	akba	Noncash Interest Expense NoncashInterestExpense	872000	USD
	us-gaap	Straight Line Rent StraightLineRent	965000	USD
	us-gaap	Straight Line Rent StraightLineRent	1164000	USD
	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	21575000	USD
	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	31116000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	5425000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	10089000	USD
	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	21338000	USD
	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	10954000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12506000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11780000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-490000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	240000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8152000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	251000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	35710000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5680000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3301000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3277000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4149000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-57000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1120000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4979000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15706000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13611000	USD
	akba	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	804000	USD
	akba	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	869000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12092000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14879000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-133887000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52369000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49950000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	40000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	245000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39941000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49750000	USD
	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44783000	USD
	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	0	USD
	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	66696000	USD
	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	198883000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	367000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	451000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	821000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111846000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200155000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17900000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	98036000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231132000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149804000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	249032000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247840000	USD
	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	68000	USD
	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	75000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Organization and Operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people living with kidney disease. Akebia’s lead investigational product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease, or CKD. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, or HIF, which can lead to red blood cell, or RBC, production and improved oxygen delivery to tissues. Vadadustat is approved and marketed in Japan as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for vadadustat in March of 2021 for the treatment of anemia due to CKD in adult patients with CKD on dialysis, or DD-CKD, and adult patients with CKD not on dialysis, or NDD-CKD. The Company's NDA submission was accepted for filing by the FDA in May 2021 and </span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the time of filing the NDA, the FDA indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for vadadustat. The FDA also assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022. In addition, the Company has a commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric citrate), which is currently approved by the FDA and marketed for two indications in the United States: the control of serum phosphorus levels in DD-CKD adult patients and the treatment of iron deficiency anemia, or IDA, in NDD-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients and the improvement of hyperphosphatemia in adult patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan to the Company’s Japanese partners Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, on December 12, 2018 following the consummation of a merger with Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from Mitsubishi Tanabe Pharma Corporation, or MTPC, from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date and may never generate profits from product sales. Vadadustat and the Company’s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat or any other potential product candidate, it may be unable to achieve profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s management completed its going concern assessment in accordance with ASC 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 205-40. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. There can be no assurance, however, that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund the Company’s operating plan for the period anticipated by the Company or that additional funding will be available on terms acceptable to the Company, or at all. The Company will require additional capital to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired. The Company expects to finance future cash needs through product revenue, public or private equity or debt transactions, payments from its collaborators, strategic transactions, or a combination of these approaches. However, adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital in sufficient amounts when needed or on attractive terms, it may not be able to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired.</span></div>
	akba	Operating Plan Sufficiently Funded By Cash Resources Period OperatingPlanSufficientlyFundedByCashResourcesPeriod	P12M
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payor mix, reserves and allowances, intangible assets and goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div>
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	41363000	USD
	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	78863000	USD
	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	806000	USD
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	73098000	USD
CY2021Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	47934000	USD
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	31543000	USD
	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	74087000	USD
	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	651000	USD
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	62177000	USD
CY2020Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	44104000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11869000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16598000	USD
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	28467000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5822000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	16964000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	10895000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	22186000	USD
CY2021Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2020Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	3555000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	3263000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity	13000000.0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity	150000000.0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Percentage Of Royalty Payments To Be Received Contingent On Reaching Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity	0.85
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44800000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Proceeds Contingent On Annual Sales Milestones ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones	5000000.0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	44800000	USD
CY2021Q2	akba	Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage	0.193
CY2020Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	0	USD
	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44783000	USD
	akba	Contractual Arrangement Royalties Agreement Royalties Earned And Payable ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable	116000	USD
	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	4427000	USD
CY2021Q2	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	49094000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	246992000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	246992000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q2	akba	Cash Cash Equivalents And Short Term Investments Amortized Cost CashCashEquivalentsAndShortTermInvestmentsAmortizedCost	246992000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	246992000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228698000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	228698000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	39979000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39992000	USD
CY2020Q4	akba	Cash Cash Equivalents And Short Term Investments Amortized Cost CashCashEquivalentsAndShortTermInvestmentsAmortizedCost	268677000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	268690000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2021Q2	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	97063000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	2420000	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	80000	USD
CY2021Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	2500000	USD
CY2021Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-570000	USD
CY2021Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1930000	USD
CY2021Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2060000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2542000	USD
CY2021Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	78287000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	64076000	USD
CY2021Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16716000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19691000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000.0	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9100000	USD
CY2020Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	86309000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	37898000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	61017000	USD
CY2021Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	59165000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25292000	USD
CY2021Q2	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	97063000	USD
CY2020Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	86309000	USD
CY2021Q2	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	5400000	USD
CY2020Q2	us-gaap	Inventory Write Down InventoryWriteDown	9900000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	10100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	214148000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	69438000	USD
CY2020Q4	akba	Finite Lived Intangible Assets Adoption Adjustment FiniteLivedIntangibleAssetsAdoptionAdjustment	-540000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	144170000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000000.0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18200000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	55100000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	55100000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q2	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	38433000	USD
CY2020Q4	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	38049000	USD
CY2021Q2	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	16034000	USD
CY2020Q4	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	28986000	USD
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8238000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14402000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5575000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5286000	USD
CY2021Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2807000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2998000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1416000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3271000	USD
CY2021Q2	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	1288000	USD
CY2020Q4	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	514000	USD
CY2021Q2	us-gaap	Postemployment Benefits Liability Current PostemploymentBenefitsLiabilityCurrent	649000	USD
CY2020Q4	us-gaap	Postemployment Benefits Liability Current PostemploymentBenefitsLiabilityCurrent	497000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9239000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8644000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111742000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	130624000	USD
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148074085	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148074085	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169651423	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169651423	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	USD
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3300000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3300000	USD
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	USD
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	3500000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	3500000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3582000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	902000	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear	2680000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7328000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1824000	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Due Net Year One LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne	5504000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5954000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	307000	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Due Net Year Two LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo	5647000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5746000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Due Net Year Three LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree	5746000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5823000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Due Net Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour	5823000	USD
CY2021Q2	akba	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	4052000	USD
CY2021Q2	akba	Lessor Operating Lease Payment To Be Received Due After Year Four LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour	0	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Due Net After Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour	4052000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	32485000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	3033000	USD
CY2021Q2	akba	Lessee Operating Lease Liability Payments Due Net LesseeOperatingLeaseLiabilityPaymentsDueNet	29452000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	32485000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4836000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	27649000	USD
CY2021Q2	akba	Purchase Committed Program Remaining Contract Costs PurchaseCommittedProgramRemainingContractCosts	8300000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	187600000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17616760	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16541685	shares

Files In Submission

Name	View Source	Status
0001628280-21-015865-index-headers.html	Edgar Link	pending
0001628280-21-015865-index.html	Edgar Link	pending
0001628280-21-015865.txt	Edgar Link	pending
0001628280-21-015865-xbrl.zip	Edgar Link	pending
akba-20210630.htm	Edgar Link	pending
akba-20210630.xsd	Edgar Link	pending
akba-20210630_cal.xml	Edgar Link	unprocessable
akba-20210630_def.xml	Edgar Link	unprocessable
akba-20210630_htm.xml	Edgar Link	completed
akba-20210630_lab.xml	Edgar Link	unprocessable
akba-20210630_pre.xml	Edgar Link	unprocessable
exhibit101-amendment1tosup.htm	Edgar Link	pending
exhibit311-q22021.htm	Edgar Link	pending
exhibit312-q22021.htm	Edgar Link	pending
exhibit321-q22021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKBA
Akebia Therapeutics, Inc. Stock $akba

2021 Q2 Form 10-Q Financial Statement

#000162828021015865 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA Akebia Therapeutics, Inc. Stock $akba

2021 Q2 Form 10-Q Financial Statement

#000162828021015865 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA
Akebia Therapeutics, Inc. Stock $akba